Stress and Anxiety Patient Study

Recruitment is set to begin in the coming weeks for a Phase IV patient study to evaluate the ability of Canopus’ Neutraceutical product, Total Calm and Focus™ to alleviate stress and anxiety in patients.

Read more...

Update from Phase II Hepatitis C Clinical Trial in the US

Recruitment of patients has begun for the second phase of Canopus’ Hepatitis C patient study at the Brooke Army Medical Center in Texas. This new wave of patients will evaluate the combination of Canopus’ Hepatitis C drug candidate, CB5300 with the well known statin, fluvastatin.

Read more...

Preliminary Results from Phase II Oltipraz/Mucositis Clinical Trial in South Africa

Canopus’ Phase II mucositis clinical trial began in November 2009. Oltipraz administered in the form of an oral rinse is being evaluated in head and neck cancer patients receiving radiation and chemotherapy treatment. All patients receiving oltipraz prior to radiation were protected from mucositis and all completed the entire course of radiation therapy.

Read more...

Future Projects

Canopus has initiated several research and development studies for 2010

Read more...

Discovery of Natural Antibiotic

Canopus has recently identified a novel, naturally occurring antibacterial agent. This compound is itself a gram-positive actinomycete which was screened for biological activity, in particular antimicrobial activity.

Read more...

United States Office
Canopus BioPharma Inc
12400 Ventura Blvd
Suite 426,
Studio City
CA 91604
info@canopusbiopharma.com

European Headquarters
Canopus BioPharma Inc
Baybush, Straffan
Co. Kildare, Ireland
Telephone: +353 1 627 2636
Fax: +353 1 627 9028
info@canopusbiopharma.com

Australian Office
Canopus BioPharma Inc
Kenilworth Stn, PO Box 716,
Oxley Street, Bourke,
NSW 2830, Australia
Tel: +61 2 6874 7830
Fax: +61 2 6874 7884

South African Office
Canopus BioPharma Inc
P.O.Box. 92051
Flaming Rock Cresent
Mooikloof 0059
Pretoria